Implications of Evolving Disease Classification for Drug Approval in Juvenile Idiopathic Arthritis. [PDF]
Paediatr Drugs, 2022 Case SM, Nigrovic PA.
europepmc +1 more source
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
I-ACT for Children: helping close the gap in drug approval for adults and children. [PDF]
Pediatr Res, 2023 Coppes MJ, Jackson C, Connor EM.
europepmc +1 more source
Molecular Oncology, EarlyView.RNA profiling of circulating extracellular vesicles (EVs) from blood samples of men undergoing prostate biopsy identifies transcripts associated with clinically significant prostate cancer. Integrative analysis with public tumor datasets links EV‐derived gene signatures to tumor stage and progression‐free survival, highlighting CASP3, XRCC2, and RIT1 ...
Stefan Werner +14 more
wiley +1 more source
Analysis of safety specifications in risk management plan at the time of drug approval and addition of clinically significant adverse reactions in the package insert post-approval in Japan. [PDF]
Pharmacol Res Perspect, 2023 Saito R, Miyazaki S.
europepmc +1 more source
Molecular Oncology, EarlyView.Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary +1 more
wiley +1 more source
DrugReasoner: Interpretable drug approval prediction with a reasoning-augmented language model. [PDF]
PLoS OneGhaffarzadeh-Esfahani M +5 more
europepmc +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
Trends, lag and characteristics of rare disease drug approval in the USA and China, 1983-2022. [PDF]
Orphanet J Rare DisWang S +11 more
europepmc +1 more source
Letter comments on: "Twelve years of European cancer drug approval-a systematic investigation of the 'magnitude of clinical benefit'". [PDF]
ESMO Open, 2022 Müller B, Estay R.
europepmc +1 more source